Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients

Exclusion Criteria

• •Pregnant or lactating women.
• •Active or untreated CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments.
• •Patients with hypertension who could not be well controlled by antihypertensive drugs (systolic blood pressure \> 150 mmHg, diastolic blood pressure \> 100 mmHg), patients with myocardial infarction, arrhythmias with poor control (including QTC interval \> 450 ms) and cardiac insufficiency of grade II according to NYHA standard.
• •with bleeding tendency or undergoing thrombolysis or anticoagulation therapy.
• •serious uncontrolled intercurrence infection.
• •Proteinuria ≥ 2+ (1.0g/24hr).
• •Have evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness.
• •Within 6 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.
• •Have a history of mental illness or psychotropic drug abuse.
• •Patients with a history of immunodeficiency(or autoimmue disease), or other acquired congenital immunodeficiency diseases, or a history of organ transplantation and hematopoietic stem cell transplantation.
• •Patients who are allergic to components of Capecitabine preparations, Oxaliplatin injection and anlotinib preparations.
• •According to the researchers' judgment, there are serious concomitant diseases that endanger patient safety or prevent patients from completing the study.
• •Patients who have received prior systemic chemotherapy, targeted therapy, immunity therapy or any medication within 30 days.